Precision Medicine is one of the most impactful global opportunities in healthcare. We can debate the name, whether it is precision, stratified or personal but at the highest strategic level, we all share a common goal to enable a world where healthcare is informed by each person unique clinical, molecular and lifestyle information.
Precision Medicine will spur a revolution in healthcare, bringing the prospects of earlier, pre-symptomatic diagnosis, more effective treatment, significant cost savings for the NHS and all the above combined with better patient outcomes.
Moreover, Precision Medicine will reach the global market value of £134 billion by 2025 thus contributing to unprecedented developments in Life Sciences industry, including new jobs creation, and a significant economic growth. The UK is in a prime position to lead on Precision Medicine globally due to the NHS facilitating advanced health data management, excellent genomics and other omics, new imaging modalities and major advances in the artificial intelligence applied to diagnostics. All the above is supported by the triple helix approach, which involves close collaborations among academic researchers, the NHS and industry.
The Covid-19 pandemic has made a major contribution to the UK molecular diagnostic capability. This legacy includes very high throughput laboratories, which should become key building blocks for the UK cutting edge Precision Medicine strategy for the next decade and beyond.